Hansa Biopharma Ab Stock Beta
HNSBF Stock | USD 2.93 0.00 0.00% |
Hansa Biopharma AB fundamentals help investors to digest information that contributes to Hansa Biopharma's financial success or failures. It also enables traders to predict the movement of Hansa Pink Sheet. The fundamental analysis module provides a way to measure Hansa Biopharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Hansa Biopharma pink sheet.
Hansa |
Hansa Biopharma AB Company Beta Analysis
Hansa Biopharma's Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current Hansa Biopharma Beta | 0.88 |
Most of Hansa Biopharma's fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Hansa Biopharma AB is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
Competition |
In accordance with the recently published financial statements, Hansa Biopharma AB has a Beta of 0.8831. This is 2.69% higher than that of the Healthcare sector and 36.47% lower than that of the Biotechnology industry. The beta for all United States stocks is notably lower than that of the firm.
Hansa Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Hansa Biopharma's direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Hansa Biopharma could also be used in its relative valuation, which is a method of valuing Hansa Biopharma by comparing valuation metrics of similar companies.Hansa Biopharma is currently under evaluation in beta category among related companies.
Hansa Biopharma returns are very sensitive to returns on the market. As the market goes up or down, Hansa Biopharma is expected to follow.
Hansa Fundamentals
Return On Equity | -0.89 | |||
Return On Asset | -0.27 | |||
Current Valuation | 189.89 M | |||
Shares Outstanding | 52.44 M | |||
Shares Owned By Insiders | 7.37 % | |||
Shares Owned By Institutions | 41.33 % | |||
Price To Earning | (46.57) X | |||
Price To Book | 6.59 X | |||
Price To Sales | 16.29 X | |||
Revenue | 33.88 M | |||
Gross Profit | 116.05 M | |||
EBITDA | (538.83 M) | |||
Net Income | (548.28 M) | |||
Cash And Equivalents | 60.15 M | |||
Cash Per Share | 1.58 X | |||
Debt To Equity | 2.29 % | |||
Current Ratio | 6.42 X | |||
Book Value Per Share | 1.50 X | |||
Cash Flow From Operations | (481.17 M) | |||
Earnings Per Share | (0.65) X | |||
Number Of Employees | 150 | |||
Beta | 0.88 | |||
Market Capitalization | 274.8 M | |||
Total Asset | 1.01 B | |||
Working Capital | 86 M | |||
Current Asset | 105 M | |||
Current Liabilities | 19 M | |||
Net Asset | 1.01 B |
About Hansa Biopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Hansa Biopharma AB's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Hansa Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Hansa Biopharma AB based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Hansa Biopharma in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Hansa Biopharma's short interest history, or implied volatility extrapolated from Hansa Biopharma options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hansa Biopharma AB. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. Note that the Hansa Biopharma AB information on this page should be used as a complementary analysis to other Hansa Biopharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Complementary Tools for Hansa Pink Sheet analysis
When running Hansa Biopharma's price analysis, check to measure Hansa Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hansa Biopharma is operating at the current time. Most of Hansa Biopharma's value examination focuses on studying past and present price action to predict the probability of Hansa Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hansa Biopharma's price. Additionally, you may evaluate how the addition of Hansa Biopharma to your portfolios can decrease your overall portfolio volatility.
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |